Given our identification of putative GRNs in both murine and human treatment-resistant tumors, we explored the expression of several prostate cancer targets in our dataset, notably FOLH1 (PSMA), STEAP1/STEAP2, TACSTD2 ((TROP2)), CEACAM5, and DLL3, all of which have drug candidates in various stages of clinical development (1, , , –5). This evidence concerns the gene TACSTD2 and prostate carcinoma.